885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab

Antzeko izenburuak

• Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2− MBC patients living in disadvantaged neighborhoods
  nork: Filipa Lynce, et al.
  Argitaratua: (2025-07-01)
• Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer
  nork: Adam M. Brufsky, et al.
  Argitaratua: (2025-04-01)
• Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer
  nork: Jiaming Zhu, et al.
  Argitaratua: (2026-02-01)
• Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2− bone-only metastatic breast cancer
  nork: Adam Brufsky, et al.
  Argitaratua: (2026-04-01)
• Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
  nork: Hope S. Rugo, et al.
  Argitaratua: (2022-10-01)